On page 2638 in the 23 October 2014 issue, there is an error in Table 1. In the “Phase” column, the entry for fedratinib (SAR302503), which reads “2 (withdrawn),” should read “3 (withdrawn).” The corrected table is shown below. The error has been corrected in the online version, which now differs from the print version.

Table 1

JAK inhibitors tested in clinical trials in MF

Agent Other targets Phase 
Ruxolitinib JAK1 3 (approved) 
Fedratinib (SAR302503) FLT3, RET 3 (withdrawn) 
Pacritinib (SB1518) FLT3 
Momelotinib (CYT387) JAK1, JNK1, TYK2, CDK2, RICJ2 
Lestaurtinib (CEP-701) FLT3, TRKA 2 (withdrawn) 
AZD1480 JAK1, JAK3, FLT4, FGFR1, TRKA 
Gandotinib (LY2784544) — 1 (withdrawn) 
XL019 — 1 (withdrawn) 
NS-018 SRC, FLT3, ABL 1/2 
BMS-911543 — 1/2 (withdrawn) 
Agent Other targets Phase 
Ruxolitinib JAK1 3 (approved) 
Fedratinib (SAR302503) FLT3, RET 3 (withdrawn) 
Pacritinib (SB1518) FLT3 
Momelotinib (CYT387) JAK1, JNK1, TYK2, CDK2, RICJ2 
Lestaurtinib (CEP-701) FLT3, TRKA 2 (withdrawn) 
AZD1480 JAK1, JAK3, FLT4, FGFR1, TRKA 
Gandotinib (LY2784544) — 1 (withdrawn) 
XL019 — 1 (withdrawn) 
NS-018 SRC, FLT3, ABL 1/2 
BMS-911543 — 1/2 (withdrawn)